McKesson's fiscal first quarter results were strong, with record revenue growth and increased full-year guidance, driven by robust segment performance and strategic acquisitions. However, the company faced challenges such as the impact of Rite Aid's bankruptcy and a decrease in international operating profit due to divestitures.

Company Guidance

During McKesson's First Quarter Fiscal 2026 Earnings Call, the company provided robust financial guidance, reflecting strong performance across its segments. The company reported a 23% increase in consolidated revenues to $97.8 billion, with adjusted operating profit rising by 9% to $1.4 billion. McKesson raised its full-year earnings guidance to a range of $37.10 to $37.90 per diluted share, up from the previous range of $36.90 to $37.70. The U.S. Pharmaceutical segment, a major contributor, saw a 25% revenue increase, largely driven by prescription volume growth and specialty products distribution. The Prescription Technology Solutions segment achieved a 16% revenue growth, bolstered by demand for access solutions, while the Medical-Surgical Solutions segment posted a 22% increase in operating profit due to cost optimization efforts. The International segment, despite facing divestitures, maintained stable performance. Additionally, McKesson's strategic acquisitions, such as PRISM Vision and Core Ventures, are expected to significantly contribute to the company's operating profit growth, reinforcing its commitment to long-term strategic priorities in oncology and biopharma services.

Record Revenue Growth

McKesson reported record consolidated revenues of $97.8 billion, an increase of 23% over the prior year.

Raised Full Year Guidance

The company raised its full year guidance to $37.10 to $37.90, up from the previous range of $36.90 to $37.70.

Strong Segment Performance

Three of McKesson's segments delivered double-digit growth in adjusted operating profit.

Oncology and Biopharma Services Expansion

Completed acquisition of a controlling interest in Core Ventures and PRISM Vision, expanding the oncology and ophthalmology platforms.

Prescription Technology Solutions Growth

The segment delivered double-digit growth in revenue and adjusted operating profit, driven by increased demand for access solutions.

U.S. Pharmaceutical Revenue Increase

U.S. Pharmaceutical revenues increased 25% to $90 billion, driven by increased prescription volumes and growth in oncology and specialty products.

Operational Efficiency Improvements

McKesson continues to improve operational leverage through automation investments, achieving up to 90% automation in some distribution centers.

McKesson (MCK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MCK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2026 (Q2)	8.86 / -	7.07	―	―	―
Aug 06, 2025	2026 (Q1)	8.14 / 8.26	7.88	4.82% (+0.38)
May 08, 2025	2025 (Q4)	9.83 / 10.12	6.18	63.75% (+3.94)
Feb 05, 2025	2025 (Q3)	7.99 / 8.03	7.74	3.75% (+0.29)
Nov 06, 2024	2025 (Q2)	6.88 / 7.07	6.23	13.48% (+0.84)
Aug 07, 2024	2025 (Q1)	7.21 / 7.88	7.27	8.39% (+0.61)
May 07, 2024	2024 (Q4)	6.36 / 6.18	7.19	-14.05% (-1.01)
Feb 07, 2024	2024 (Q3)	7.04 / 7.74	6.9	12.17% (+0.84)
Nov 01, 2023	2024 (Q2)	6.15 / 6.23	6.06	2.81% (+0.17)
Aug 02, 2023	2024 (Q1)	5.87 / 7.27	5.83	24.70% (+1.44)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MCK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$702.92	$662.46	-5.76%
May 08, 2025	$688.74	$691.95	+0.47%
Feb 05, 2025	$604.90	$597.78	-1.18%
Nov 06, 2024	$546.89	$604.83	+10.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mckesson Corp. (MCK) report earnings?

Mckesson Corp. (MCK) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).

What is Mckesson Corp. (MCK) earnings time?

Mckesson Corp. (MCK) earnings time is at Nov 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MCK EPS forecast?

MCK EPS forecast for the fiscal quarter 2026 (Q2) is 8.86.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing